Welcome to our dedicated page for UroGen Pharma Ltd. SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UroGen Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UroGen Pharma Ltd.'s regulatory disclosures and financial reporting.
UroGen Pharma Ltd. reported first-quarter 2026 revenue of $50.9 million, significantly higher than the same period in 2025, driven by sales of Jelmyto and the newly approved bladder cancer drug Zusduri. Jelmyto contributed $21.7 million and Zusduri $29.2 million in product sales.
The company posted a net loss of $23.6 million, narrower than the prior-year period, as higher gross profit was partly offset by increased selling, general and administrative spending to support commercialization. Cash, cash equivalents and marketable securities totaled $140.3 million as of March 31, 2026, while long-term debt rose to $189.5 million after closing a new $200 million term loan with Pharmakon that refinanced existing borrowings and added liquidity.
UroGen also carries a prepaid forward obligation of $128.2 million tied to future Jelmyto and Zusduri net sales. Despite an accumulated deficit of $983.3 million, management believes current cash and investments can fund operations beyond one year, assuming continued uptake of its approved products.
UroGen Pharma reported strong first quarter 2026 results driven by the launch of ZUSDURI and growth in JELMYTO. Revenue rose to $50.9 million from $20.3 million a year earlier, a 152% year-over-year increase, as ZUSDURI sales more than doubled quarter-over-quarter.
Net loss narrowed to $23.6 million, or ($0.47) per share, compared with a net loss of $43.8 million, or ($0.92) per share, in the prior-year quarter. Cash, cash equivalents and marketable securities were $140.3 million as of March 31, 2026, up from $120.5 million at year-end 2025.
The company reaffirmed 2026 JELMYTO net product revenue guidance of $97–$101 million and expects full-year 2026 operating expenses of $240–$250 million, including $20–$24 million of non-cash share-based compensation. Management highlighted accelerating ZUSDURI adoption, advancing pipeline programs UGN-103, UGN-104 and UGN-501, and an expanded debt facility with Pharmakon Advisors.
UroGen Pharma Ltd. is soliciting proxies for its 2026 Annual Meeting of Shareholders, to be held virtually on June 22, 2026 at 10:00 a.m. Eastern Time. Shareholders of record as of April 29, 2026, when 48,721,701 ordinary shares were outstanding, may attend online, ask questions and vote.
Key items include electing seven directors, approving amended Articles of Association to align shareholder proposal rights with Israeli Companies Law, and approving a Compensation Policy amendment clarifying director and officer insurance, exculpation and indemnification terms.
Shareholders are also asked to approve an amendment to the 2017 Equity Incentive Plan to add 1,000,000 ordinary shares for employee and director equity awards, give advisory approval of named executive officer compensation, and approve PricewaterhouseCoopers LLP as independent auditor until the 2027 annual meeting. The proxy explains voting methods, broker non-votes, quorum and required majorities, including special voting rules for Proposal 3.
BlackRock, Inc. reports beneficial ownership of UROGEN PHARMA LTD common stock totaling 2,519,771 shares as of 03/31/2026. The filing shows BlackRock holds 5.2% of the class with 2,461,477 shares of sole voting power and sole dispositive power over 2,519,771 shares.
UroGen Pharma Ltd. is soliciting shareholder votes at its virtual 2026 Annual Meeting on June 22, 2026. The Board asks shareholders to elect seven directors, approve amended Articles of Association, approve a Compensation Policy amendment, authorize a 1,000,000-share increase to the 2017 Equity Incentive Plan, approve executive compensation (advisory) and ratify PwC as auditor.
The Board recommends FOR each proposal; the Company intends to register the additional 1,000,000 shares under Form S-8 if shareholders approve the plan increase.
UroGen Pharma Ltd. files its annual report describing a focused uro-oncology business built around its RTGel reverse-thermal hydrogel drug-delivery platform. The company develops therapies that keep chemotherapy and immunotherapy in the urinary tract longer, aiming to improve tumor control with minimally invasive treatments.
UroGen’s approved products are Jelmyto for low-grade upper tract urothelial carcinoma and Zusduri for recurrent low-grade intermediate-risk non–muscle invasive bladder cancer, both RTGel-based mitomycin formulations designed for chemoablation instead of repeated surgery. The report details broad payer coverage, dedicated commercial infrastructure, and ongoing registries and follow-up studies to characterize long-term outcomes.
The pipeline includes next-generation mitomycin products UGN‑103 and UGN‑104 under a medac collaboration, and UGN‑501, an oncolytic virus acquired from IconOVir to target high‑grade disease and potentially other cancers. UroGen emphasizes its intellectual property estate, regulatory pathways (including 505(b)(2), orphan exclusivity and Orange Book listings), and experience navigating FDA approval, fast-track and breakthrough processes.
UroGen Pharma reported full-year 2025 revenue of $109.8 million, up from $90.4 million in 2024, driven by the FDA approval and commercial launch of bladder cancer drug ZUSDURI and growth of kidney cancer therapy JELMYTO.
Research and development expenses rose to $67.1 million and selling, general and administrative costs increased to $155.1 million, reflecting clinical programs and launch investments. The company posted a net loss of $153.5 million, or $3.19 per share, and ended 2025 with $120.5 million in cash, cash equivalents and marketable securities.
Management highlighted 2026 as a pivotal year for the ZUSDURI rollout, with early signs of increasing physician adoption following permanent J‑Code reimbursement. UroGen guided 2026 JELMYTO net product sales to $97–$101 million and expects operating expenses of $240–$250 million while advancing late‑stage candidates UGN‑103 and UGN‑104 toward planned regulatory milestones.
UroGen Pharma Ltd. entered into a new secured term loan agreement providing up to $250,000,000 in borrowings through two tranches. A $200,000,000 Tranche A loan was funded immediately, with Tranche B of $50,000,000 available at the borrower’s election through June 30, 2027, subject to conditions.
The Tranche A proceeds refinance an existing $125,000,000 term loan and support general corporate and working capital needs; Tranche B would also fund general corporate purposes. The debt carries a fixed 8.25% annual interest rate, quarterly payments, and matures five years after the Tranche A closing date, with principal amortization beginning in the first quarter of 2030.
The facility is guaranteed by UroGen Pharma Ltd., is secured by substantially all tangible and intangible assets (including intellectual property), and includes customary affirmative and restrictive covenants but no financial covenants. Prepayments trigger a 1% exit fee and, if made within one year of each tranche’s closing, a makewhole equal to foregone interest, and a change of control requires repayment.
UroGen Pharma Ltd. director exercises RSUs into shares. On February 26, 2025, director James A. Robinson Jr. exercised 2,000 Restricted Stock Units, each representing a right to receive one ordinary share. This conversion resulted in the acquisition of 2,000 ordinary shares at a stated price of $0.00 per share.
After these transactions, his reported holdings increased to 4,000 Restricted Stock Units and 4,000 ordinary shares, all held directly. The activity reflects an equity award conversion rather than an open-market purchase or sale.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
UroGen Pharma Ltd. reported that Chief Executive Officer Elizabeth A. Barrett received a grant of 153,195 restricted stock units on January 31, 2026. Each RSU represents the right to receive one ordinary share at no purchase price. One-third of the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, aligning the CEO’s compensation with the company’s long-term performance.